Background and purpose: Antiemetic guidelines suggest daily prophylaxis with a serotonin3 receptor antagonist (5-HT3RA) as an option for patients receiving long-course neoadjuvant radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal cancer. despite the risks that 5-HT3RA-induced constipation may pose. We explored the incidence of patient-reported vomiting. ret... https://www.lorenametaute.com/